Fig. 2 | Scientific Reports

Fig. 2

From: Multiomics Mendelian randomization integrating pQTL, eQTL and mQTL data revealed BTN3A2 as a potential drug target for nephrolithiasis

Fig. 2

Results of preliminary and replication MR analyses. MR Mendelian randomization, FDR false discovery rate, BTN2A1 butyrophilin subfamily 2 member A1, BTN3A2 butyrophilin subfamily 3 member A2, ERBB4 receptor tyrosine-protein kinase erbB-4, FKBPL FK506-binding protein-like, GPC5 glypican 5, HEXIM1 HEXIM P-TEFb complex subunit 1, HLA-E HLA class I histocompatibility antigen, alpha chain E, UMOD uromodulin, PPRTs plasma protein-related targets, SNPs single-nucleotide polymorphisms. In the primary analyses, the P value threshold for Bonferroni correction was 1.19e-05 (0.05/4197), and the P value threshold for FDR correction was 0.05. In the replication analyses, since there were 8 plasma proteins included in the analyses, the P value threshold for Bonferroni correction was 6.25e-03 (0.05/8), and the P value threshold for FDR correction was 0.05.

Back to article page